Asset sale Completed
Eli Lilly and Company acquisition of Sangamo Therapeutics capsid delivery, zinc finger, modular integrase platforms and prion disease program
Announced 23 Jun 2026 · OTC: SGMOQ
Advisers
Sangamo Therapeutics capsid delivery, zinc finger, modular integrase platforms and prion disease program
Target
Not disclosed
Eli Lilly and Company
Acquirer
Other advisers
- Financial adviser
- Target
- Sangamo Therapeutics capsid delivery, zinc finger, modular integrase platforms and prion disease program
- Acquirer
- Eli Lilly and Company
- Seller
- Sangamo Therapeutics
- Target based in
- United States
- Buyer based in
- United States
- Seller based in
- United States
- Completed
- Sep 2026
- Sector
- Biotech
- Tags
- Biotech, Life Sciences
In the league tables
Similar deals
- BRUKER acquisition of MIMETAS Aug 2026 · Life Sciences
- Oberland Capital Management stake in MeiraGTx Holdings Jul 2026 · Biotech
- Ligand Pharmaceuticals acquisition of XOMA Royalty Apr 2026 · US$739m · Specialty finance and leasing
- XRA 7 Corp. acquisition of Generation Bio Co. Dec 2025 · Biotech
- Invex Therapeutics acquisition of Rekover Therapeutics Oct 2026 · Healthcare
Sources
- 23 Jun 2026 Eli Lilly Enters Into Agreement to Acquire Sangamo Assets as Stalking Horse Bidder in Chapter 11 Auction paulweiss.com
- Sep 2026 Raymond James: September 2026 Sangamo Therapeutics acquired by Lilly PTC Therapeutics received DIP financing from JMB Capital Future Solution Investments raymondjames.com

